Author(s)

Lei Shi ¹, Qiyang Ding ¹, Ji Xia ², Nisha Wang ², Xiaohong Lu ³

Affiliation(s)

¹ Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
² Xi'an Jiaotong University, Xi'an, Shaanxi, 710049, China
³ Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712000, China

Corresponding Author

Xiaohong Lu

ABSTRACT

China stands out as a nation with a particularly high prevalence of diabetes, making it one of the global leaders in the number of individuals living with this condition. A significant and debilitating complication of diabetes is Diabetic Associated Cognitive Dysfunction (DACD), which in its most advanced form, dementia, becomes the primary cause of mortality among diabetics, second only to cancer. Despite the gravity of this issue, existing treatments for DACD have fallen short in their effectiveness, underscoring the pressing need for the identification of novel therapeutic targets. In this context, AdipoRon, a small molecule that activates adiponectin receptors AdipoR1 and AdipoR2, emerges as a promising candidate for addressing both diabetes and the associated cognitive decline. This comprehensive review delves into the latest research advancements regarding AdipoRon, highlighting the challenges and future research avenues that must be pursued to facilitate its transition from bench to bedside. The aim is to equip healthcare professionals with the knowledge necessary for the effective prevention and management of DACD.

KEYWORDS

Adiponectin, AdipoRon, Diabetes-related Cognitive Dysfunction, Targeting

CITE THIS PAPER

Lei Shi, Qiyang Ding, Ji Xia, Nisha Wang, Xiaohong Lu. Adiponectin and Its Receptor Agonist (AdipoRon) in the Treatment of Diabetes-Associated Cognitive Dysfunction: Research Progress. MEDS Clinical Medicine (2024) Vol. 5: 35-41. DOI: http://dx.doi.org/10.23977/medsc.2024.050506.

REFERENCES

[1] Sun, H. et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119 (2022).
[2] Li, Y., Wang, J. & Wei, X. Confirmation of the depth of the endotracheal tube: Where should the cuff be? Resuscitation 88, e7 (2015).
[3] Albai, O., Frandes, M., Timar, R., Roman, D. & Timar, B. Risk factors for developing dementia in type 2 diabetes mellitus patients with mild cognitive impairment. Neuropsychiatr Dis Treat 15, 177-175 (2019).
[4] Koekkoek, P. S., Kappelle, L. J., van den Berg, E., Rutten, G. E. H. M. & Biessels, G. J. Cognitive function in patients with diabetes mellitus: Guidance for daily care. The Lancet Neurology 14, 329-340 (2015).
[5] American Diabetes Association. 12. older adults: standards of medical care in diabetes—2019. Diabetes Care 42, S139-S147 (2019).
[6] Committee report: Glycemic targets for elderly patients with diabetes: japan diabetes society (JDS)/japan geriatrics society (JGS) joint committee on improving care for elderly patients with diabetes. Journal of Diabetes Investigation 8, 126-128 (2017).
[7] de Galan, B. E. et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: preterax and diamicron modified release controlled evaluation (ADVANCE) trial. Diabetologia 52, 2328-2336 (2009).
[8] Pearson, S. J. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: An epidemiological analysis of linked primary care records. The Lancet Diabetes & Endocrinology 9, 165-173 (2021).
[9] Sinclair, A. J., Hillson, R., Bayer, A. J., & National Expert Working Group. Diabetes and dementia in older people: A best clinical practice statement by a multidisciplinary national expert working group. Diabetic Medicine: A Journal of the British Diabetic Association 31, 1024-1031 (2014).
[10] T, C., Hc, G. & Jd, W. Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies. Diabetologia 48, (2005).
[11] Xu, W. et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 59, 2928-2935 (2010).
[12] Edersheim, J., Murray, E. D., Padmanabhan, J. L. & Price, B. H. Protecting the health and finances of the elderly with early cognitive impairment. The Journal of the American Academy of Psychiatry and the Law 45, 81-91 (2017).
[13] Bloemer, J. et al. Role of adiponectin in central nervous system disorders. Neural Plast. 2018, 4593530 (2018).
[14] Rizzo, M. R., Fasano, R. & Paolisso, G. Adiponectin and cognitive decline. International Journal of Molecular Sciences 21, 2010 (2020).
[15] Clain, J. et al. Distribution of adiponectin receptors in the brain of adult mouse: Effect of a single dose of the adiponectin receptor agonist, AdipoRON, on ischemic stroke. Brain Sciences 12, 680 (2022).
[16] Onodera, T. et al. PEGylated AdipoRon derivatives improve glucose and lipid metabolism under insulinopenic and high-fat diet conditions. J. Lipid Res. 62, 100095 (2021).
[17] Amatya, R., Min, K. A. & Shin, M. C. A review of glucoregulatory hormones potentially applicable to the treatment of Alzheimer's disease: mechanism and brain delivery. J. Pharm. Investig. 52, 195-216 (2022).
[18] Ng, R. C. et al. Chronic oral administration of AdipoRon reverses cognitive impairments and ameliorates neuropathology in an alzheimer’s disease mouse model. Mol. Psychiatry 26, 5669-5689 (2021).
[19] K, H. et al. Adiponectin alleviated alzheimer-like pathologies via autophagy-lysosomal activation. Aging cell 20, (2021).
[20] Zhang, C. et al. Adiponectin treatment attenuates cerebral ischemia-reperfusion injury through HIF-1α-mediated antioxidation in mice. Oxid. Med. Cell. Longev. 2021, 5531048 (2021).
[21] Zhanqin, Z. & Qiang, W. Protective Effect ofAdiponectin on Septic Cerebral Injury and its Mechanism. Yixue Yanjiu Zazhi 49, 41-45 (2020).
[22] Cheng, J. et al. Low-dose alcohol ameliorated high fat diet-induced anxiety-related behavior via enhancing adiponectin expression and activating the Nrf2 pathway. Food Funct. 12, 241-251 (2021).
[23] Miao, W. et al. Adiponectin ameliorates hypoperfusive cognitive deficits by boosting a neuroprotective microglial response. Prog. Neurobiol. 205, 102125 (2021).
[24] Ali, T. et al. Adiponectin-mimetic novel nonapeptide rescues aberrant neuronal metabolic-associated memory deficits in Alzheimer's disease. Mol Neurodegeneration 16, 23 (2021).
[25] Zheng, J. et al. AdipoRon Attenuates Neuroinflammation After Intracerebral Hemorrhage Through AdipoR1-AMPK Pathway. Neuroscience 412, 116-130 (2019).
[26] Otvos, L. Potential Adiponectin Receptor Response Modifier Therapeutics. Front. Endocrinol. 10, 539 (2019).
[27] Dai, J. et al. Multimeric adiponectin nanoparticles regulate glucose metabolism by activating phosphatidylinositol-3-kinase, protein kinase B and T-cadherin. Process Biochemistry 126, 33-40 (2023).
[28] Okada-Iwabu, M. et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 503, 493-499 (2013).
[29] Bhat, I. A., Kabeer, S. W., Reza, M. I., Mir, R. H. & Dar, M. O. AdipoRon: A Novel Insulin Sensitizer in Various Complications and the Underlying Mechanisms: A Review. CMP 13, 94-107 (2020).
[30] Ng, R. C.-L. & Chan, K.-H. Potential Neuroprotective Effects of Adiponectin in Alzheimer's Disease. Int J Mol Sci 18, 592 (2017). 
[31] Kim, Y. & Park, C. W. Mechanisms of Adiponectin Action: Implication of Adiponectin Receptor Agonism in Diabetic Kidney Disease. Int J Mol Sci 20, 1782 (2019).
[32] Zhao, Y. et al. DDAH1/ADMA Regulates Adiponectin Resistance in Cerebral Ischemia via the ROS/FOXO1/APR1 Pathway. Oxidative Medicine and Cellular Longevity 2022, 1-15 (2022).
[33] Zha, D., Wu, X. & Gao, P. Adiponectin and Its Receptors in Diabetic Kidney Disease: Molecular Mechanisms and Clinical Potential. Endocrinology 158, 2022-2034 (2017).
[34] Wu, X. et al. An Adiponectin Receptor Agonist Reduces Type 2 Diabetic Periodontitis. J Dent Res 98, 313-321 (2019).
[35] Kim, Y. et al. The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes. J Am Soc Nephrol 29, 1108-1127 (2018).
[36] Akimoto, M., Maruyama, R., Kawabata, Y., Tajima, Y. & Takenaga, K. Antidiabetic adiponectin receptor agonist AdipoRon suppresses tumour growth of pancreatic cancer by inducing RIPK1/ERK-dependent necroptosis. Cell Death Dis 9, 804 (2018).
[37] Miao, W. et al. Adiponectin ameliorates hypoperfusive cognitive deficits by boosting a neuroprotective microglial response. Progress in Neurobiology 205, 102125 (2021).
[38] Liu, B., Liu, J., Wang, J., Liu, C. & Yan, H.-J. AdipoRon improves cognitive dysfunction of alzheimer's disease and rescues impaired neural stem cell proliferation through AdipoR1/AMPK pathway. Exp. Neurol. 327, 113249 (2020).
[39] Khandelwal, M., Manglani, K., Upadhyay, P., Azad, M. & Gupta, S. AdipoRon induces AMPK activation and ameliorates alzheimer's like pathologies and associated cognitive impairment in APP/PS1 mice. Neurobiol. Dis. 174, 105876 (2022).
[40] Yu, J. et al. AdipoRon Protects Against Secondary Brain Injury After Intracerebral Hemorrhage via Alleviating Mitochondrial Dysfunction: Possible Involvement of AdipoR1-AMPK-PGC1α Pathway. Neurochem Res 44, 1678-1689 (2019).
[41] Lee, T. H. et al. Chronic AdipoRon Treatment Mimics the Effects of Physical Exercise on Restoring Hippocampal Neuroplasticity in Diabetic Mice. Mol Neurobiol 58, 4666-4681 (2021).
[42] Wang, Y. et al. AdipoRon exerts opposing effects on insulin sensitivity via fibroblast growth factor 21-mediated time-dependent mechanisms. J. Biol. Chem. 298, 101641 (2022).
[43] Nicolas, S. et al. Adiporon, an adiponectin receptor agonist acts as an antidepressant and metabolic regulator in a mouse model of depression. Transl. Psychiatry 8, 159 (2018). 

Sponsors, Associates, and Links

---

• Journal of Neurobiology and Genetics
  
  
• Medical Imaging and Nuclear Medicine
  
  
• Bacterial Genetics and Ecology
  
  
• Transactions on Cancer
  
  
• Journal of Biophysics and Ecology
  
  
• Journal of Animal Science and Veterinary
  
  
• Academic Journal of Biochemistry and Molecular Biology
  
  
• Transactions on Cell and Developmental Biology
  
  
• Rehabilitation Engineering & Assistive Technology
  
  
• Orthopaedics and Sports Medicine
  
  
• Hematology and Stem Cell
  
  
• Journal of Intelligent Informatics and Biomedical Engineering
  
  
• MEDS Basic Medicine
  
  
• MEDS Stomatology
  
  
• MEDS Public Health and Preventive Medicine
  
  
• MEDS Chinese Medicine
  
  
• Journal of Enzyme Engineering
  
  
• Advances in Industrial Pharmacy and Pharmaceutical Sciences
  
  
• Bacteriology and Microbiology
  
  
• Advances in Physiology and Pathophysiology
  
  
• Journal of Vision and Ophthalmology
  
  
• Frontiers of Obstetrics and Gynecology
  
  
• Digestive Disease and Diabetes
  
  
• Advances in Immunology and Vaccines
  
  
• Nanomedicine and Drug Delivery
  
  
• Cardiology and Vascular System
  
  
• Pediatrics and Child Health
  
  
• Journal of Reproductive Medicine and Contraception
  
  
• Journal of Respiratory and Lung Disease
  
  
• Journal of Bioinformatics and Biomedicine